benzyl (2R)-2-benzyl-3-<<(2-hydroxyethyl)methylamino>carbonyl>propionate | 122226-17-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl (2R)-2-benzyl-3-<<(2-hydroxyethyl)methylamino>carbonyl>propionate
• 英文别名: benzyl (2R)-2-benzyl-4-[2-hydroxyethyl(methyl)amino]-4-oxobutanoate
• CAS: 122226-17-9
• 化学式: C₂₁H₂₅NO₄
• 分子量: 355.434
• InChiKey: NWIPOFANPANVHL-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzyl (2R)-2-benzyl-3-<<(2-hydroxyethyl)methylamino>carbonyl>propionate 在 palladium on activated charcoal N-甲基吗啉 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 (R)-2-Benzyl-N¹-[(S)-1-[(1S,2R)-1-cyclohexylmethyl-2-((S)-3-ethyl-2-oxo-oxazolidin-5-yl)-2-hydroxy-ethylcarbamoyl]-2-(3H-imidazol-4-yl)-ethyl]-N⁴-(2-hydroxy-ethyl)-N⁴-methyl-succinamide
  参考文献：
  名称：

  Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action

  摘要：

  Incorporation of nonreactive polar functionalities at the C- and N-termini of renin inhibitors led to the development of a subnanomolar compound (21) with millimolar solubility. This inhibitor demonstrated excellent efficacy and a long duration of action upon intravenous administration to monkeys. While activity was also observed intraduodenally, a comparison of the blood pressure responses indicated low bioavailability. Subsequent experiments in rats showed that, although the compound was absorbed from the gastrointestinal tract, extensive liver extraction severely limited bioavailability.

  DOI：

  10.1021/jm00169a024
• 作为产物：
  描述：

  N-甲基-2-羟基乙胺 、 (3R)-3-Benzyloxycarbonyl-3-phenylmethylpropionic acid 在 N-甲基吗啉 、 氯甲酸异丁酯 作用下， 生成 benzyl (2R)-2-benzyl-3-<<(2-hydroxyethyl)methylamino>carbonyl>propionate
  参考文献：
  名称：

  Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action

  摘要：

  Incorporation of nonreactive polar functionalities at the C- and N-termini of renin inhibitors led to the development of a subnanomolar compound (21) with millimolar solubility. This inhibitor demonstrated excellent efficacy and a long duration of action upon intravenous administration to monkeys. While activity was also observed intraduodenally, a comparison of the blood pressure responses indicated low bioavailability. Subsequent experiments in rats showed that, although the compound was absorbed from the gastrointestinal tract, extensive liver extraction severely limited bioavailability.

  DOI：

  10.1021/jm00169a024

文献信息

• Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3-[[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-72517)
  作者：Saul H. Rosenberg、Kenneth P. Spina、Stephen L. Condon、Jim Polakowski、Zhengli Yao、Peter Kovar、Herman H. Stein、Jerome Cohen、Jennifer L. Barlow

  DOI：10.1021/jm00056a006

  日期：1993.2

  for the design of well-absorbed renin inhibitors, we have followed two strategies to improve potency while maintaining bioavailability. One process involved incorporation of an extended N-terminal residue bearing a weakly basic substituent and is exemplified by compound 25. The other approach centered on the inclusion of an N-terminal sulfonamide and culminated in the discovery of inhibitor 32 (A-72517)

  我们采用了一系列设计良好吸收肾素抑制剂的经验准则，我们遵循了两种策略来提高药效并同时保持生物利用度。一种方法涉及掺入带有弱碱性取代基的延伸的N-末端残基，并以化合物25为例。另一种方法集中于包含N-末端磺酰胺并最终发现抑制剂32（A-72517）。25和32均在大鼠和雪貂中表现出极佳的生物利用度（> 25％），并且在猴子中受到肝脏清除后，在该物种中有效。
• Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action
  作者：Saul H. Rosenberg、Keith W. Woods、Hing L. Sham、Hollis D. Kleinert、Donald L. Martin、Herman Stein、Jerome Cohen、David A. Egan、Barbara Bopp

  DOI：10.1021/jm00169a024

  日期：1990.7

  Incorporation of nonreactive polar functionalities at the C- and N-termini of renin inhibitors led to the development of a subnanomolar compound (21) with millimolar solubility. This inhibitor demonstrated excellent efficacy and a long duration of action upon intravenous administration to monkeys. While activity was also observed intraduodenally, a comparison of the blood pressure responses indicated low bioavailability. Subsequent experiments in rats showed that, although the compound was absorbed from the gastrointestinal tract, extensive liver extraction severely limited bioavailability.